Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
Status:
Completed
Trial end date:
2020-11-03
Target enrollment:
Participant gender:
Summary
This was a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine
the effect of ALXN1840 on the metabolism of celecoxib, a sensitive cytochrome P450 2C9
(CYP2C9) substrate, in healthy male and female participants. The safety and tolerability of
ALXN1840 were determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via
total molybdenum with the coadministration of celecoxib.